Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$4.8MCash on Hand
5.7mo Cash Runway
Follow DRMA by emailGet an email when DRMA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about DRMA, unsubscribe in one click. Privacy
📣 What DRMA Says Is Next
first half of 2027 · “The Company expects to launch Tome Clearing Treatment in the first half of 2027, subject to successful development and commercialization activities.”
Company press release, Nov 10, 2026 · SEC filing
first half of 2027 · “Recently, we initiated a clinical trial evaluating Tome Clearing Treatment, our second planned commercial product for the treatment of acne, which we expect to launch in the first half of 2027,” continued Mr. Proehl.”
Company press release, Nov 10, 2026 · SEC filing
first half of 2027 · “The Company expects to launch this second commercial product in the first half of 2027 .”
Company press release, Oct 29, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Clinical trial Dermata issued a press release with additional results and photos from a recent cosmetic study of Tome Foundational Treatment, its once-weekly skin renewal product launched recently. The company reports over 1,000 orders since launch. Form 8-K · SEC filing
Nov 10, 2026 ·
Earnings Reported Q3 2026 results with first product revenue of $74,000 from Tome Foundational Treatment, launched Aug 25, 2026, and cash of $5.0 million as of Sept 30, 2026, expected to fund operations into Q1 2027. SG&A rose to $2.8 million from $1.3 million. Form 8-K · SEC filing · Press release
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Aug 17, 2026 ·
Financing Dermata entered a private placement with institutional investors for 933,064 common shares and pre-funded warrants at $1.46 per share, plus series E and F warrants, for net proceeds of about $3.2 million. Company insiders bought 4,897,956 shares and warrants at $1.47. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Earnings Reported Q2 2026 results with cash of $4.4 million as of June 30, 2026, down from $7.5 million at December 31, 2025, and said cash is sufficient into Q4 2026. Launch of first product Tome Foundational Treatment expected August 25, 2026. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2025 · Phase 3 · Results Expected · DMT310-009 Topical in the Treatment of Acne Vulgaris Registry primary completion date, not a results date
May 2020 · Phase 2 · Results Expected · DMT310-003 Topical in the Treatment of Acne Vulgaris Registry primary completion date, not a results date
Dec 2018 · Phase 2 · Results Expected · DMT310-001 Topical in the Treatment of Acne Vulgaris Registry primary completion date, not a results date
Aug 2017 · Phase 2 · Results Expected · DMT210 Topical Gel in the Treatment of Acne Rosacea Registry primary completion date, not a results date
Jul 2017 · Phase 2 · Results Expected · DMT210 Topical Gel in the Treatment of Atopic Dermatitis Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not DRMA's own candidates): Hydrogen Peroxide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
DRMA holds $4.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.5M/quarter from operations,
an estimated runway of 5.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 6 months +40
ATM program on file since Jan 2026 +15
Shelf registration (S-3, Nov 2025) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued.10-Q, Nov 2026
Share count 4,930,207 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full DRMA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DRMA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.